electroCore, Inc. Announces Research Collaboration with Massachusetts General Hospital to Explore Non-Invasive Vagus Nerve St...
09 Agosto 2018 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine company, today announced a research collaboration with
Massachusetts General Hospital (MGH) through the company’s funding
of a MGH program targeting neuroinflammation. Within this
program, electroCore’s non-invasive vagus nerve stimulation (nVNS)
will be studied in preclinical settings, looking at the effects of
this novel therapeutic approach on neuroinflammatory mechanisms
which have been associated with conditions in the central nervous
system (CNS) including pain, trauma and neurodegeneration.
“We are proud to partner with a renowned research institution
like Massachusetts General Hospital, whose core scientific mission
aligns with our belief that it is through the deep understanding of
the mechanisms of potential therapies that we learn to best help
patients suffering from debilitating conditions,” said J.P. Errico,
Chief Science Officer at electroCore. “We look forward to the
outputs of our collaborative research efforts to better elucidate
the effects of non-invasive vagus nerve stimulation on
neuroinflammation, and its role in the treatment of conditions such
as Alzheimer’s disease and traumatic brain injury.”
Through a research grant, electroCore intends to provide up to
one million dollars over a four-year period to Massachusetts
General Hospital to conduct multiple preclinical studies, including
initial work initiated in the second quarter of 2018 in the
following areas:
- The effects of nVNS on persistent neuroinflammation and the
neurological outcomes after concussive traumatic brain injury;
and
- The effects of nVNS on microglia cells and their association
with the development and progression of Alzheimer’s disease.
This work follows prior preclinical studies at MGH supported by
electroCore to study neuroinflammatory mechanisms associated with
migraine and their modulation by nVNS.
“At Massachusetts General Hospital, we are committed to
deepening our understanding of disease and novel potential
therapies, and have consistently sought out partnerships that can
help us do so, especially in areas with great unmet need,” said Dr.
Cenk Ayata, Massachusetts General Hospital, who is the director of
the newly created program. “We look forward to having the
opportunity to explore the effects of this non-invasive approach to
vagus nerve stimulation on neuroinflammation, which we increasingly
understand to be a core aspect of neurologic disorders ranging from
pain, to trauma, to degeneration.”
About electroCore, Inc. electroCore, Inc.
is a commercial-stage bioelectronic medicine healthcare company
dedicated to improving patient outcomes through its non-invasive
vagus nerve stimulation (nVNS) platform therapy initially focused
on the treatment of multiple conditions. The company’s initial
commercial focus is on the acute treatment of pain associated with
migraine and episodic cluster headache in adults. For more
information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and product
development plans, its pipeline or potential markets for its
technologies, and other statements that are not historical in
nature, particularly those that utilize terminology such as
"anticipates," "will," "expects," "believes," "intends," other
words of similar meaning, derivations of such words and the use of
future dates. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue electroCore’s business and
product development plans, the inherent uncertainties associated
with developing new products or technologies, the ability to
commercialize gammaCore™, competition in the industry in which
electroCore operates and overall market conditions. Any
forward-looking statements are made as of the date of this press
release, and electroCore assumes no obligation to update the
forward-looking statements or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all
of the information set forth herein and should also refer to the
risk factor disclosure set forth in the reports and other documents
electroCore files with the SEC available at www.sec.gov.
Media ContactAlexandra CanaleGCI
Health617-921-9353Alexandra.canale@gcihealth.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024